Project Grant R43AG094412
- The National Institute on Aging (NIA) awarded a $483,346 Project Grant to Meganano Diagnostics Inc. under the Aging Research Federal Grant Program (CFDA 93.866) for the development of an RT-qPCR assay for early diagnosis of Alzheimer's disease (AD). The project aims to leverage changes in T cell receptor (TCR) clonality in peripheral blood mononuclear cells (PBMCs) as a potential biomarker for early AD detection. Preliminary research by Meganano Diagnostics has demonstrated increased TCR...
- The National Institute on Aging (NIA) awarded a $154,748 Project Grant under the Aging Research program (CFDA 93.866) to Brigham & Women's Hospital Inc. to develop an ultrasensitive blood-based diagnostic tool for accurately determining the presence and severity of Alzheimer's disease (AD). The project aims to utilize single molecule detection to measure low abundance AD protein biomarkers, particularly phosphorylated tau proteins, in blood extracellular vesicles, which can reflect protein...
- This $492,250 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) supports research to determine if regulatory T cells (Tregs) are dysfunctional in Alzheimer's disease (AD). The grant recipient, Brigham & Women's Hospital, will conduct comprehensive scientific investigations to understand the role of Tregs in AD pathology. This includes isolating and functionally assessing Tregs derived from AD patients to evaluate their potential...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $162,486.00 to support research on the role of regulatory T cells in Alzheimer's disease (AD). The grant was awarded to the Regents of the University of Minnesota, Office of Sponsored Projects Administration on November 16, 2024, with an ultimate completion date of July 31, 2027. The project aims to advance scientific understanding of the relationship between regulatory T cells and the...
- This federal Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $506,061 to Redwood Neuro Inc. to develop an innovative blood-based diagnostic platform called SIMOLISA. The goal is to revolutionize Alzheimer's disease (AD) diagnostics by enabling ultra-sensitive and affordable detection of critical AD biomarkers such as p-tau proteins and β-amyloid. Unlike current high-cost systems, SIMOLISA utilizes cost-effective materials and...
- The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $426,555 project grant to Duke University to develop a novel molecular diagnostic technology called "Cascade Amplification by Recycling Trigger Probe" (CARTP) for rapid, multiplex, and ultra-sensitive detection of circulating microRNA (miRNA) biomarkers in clinical plasma samples for the early detection of Alzheimer's disease (AD). The project aims to address the technical...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund the development of a novel "theranostic" (therapeutic and diagnostic) Chimeric Antigen Receptor (CAR) T cell platform to detect and target senescent cells associated with Alzheimer's disease and other age-related disorders. The $834,627 award, made on March 19, 2025, supports the University of Florida's research to create unique probes and a signal-sensing chemically-induced proximity...
- The National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, awarded a $1,249,957 Project Grant under CFDA 93.866 (Aging Research) to Advantage Therapeutics, Inc. in Florida. The grant aims to perform IND-enabling studies on a small molecule that is disease-modifying, low-cost, and has a long safety record for the treatment of Alzheimer's disease. The proposed molecule is designed to reduce brain inflammation and restore phagocytosis, thereby improving the...
- The National Institute on Aging (NIA) awarded a $773,816 project grant under the Aging Research federal grant program (CFDA 93.866) to the University of California, Irvine (UCI) to conduct comparative studies on new tau-directed Alzheimer's disease (AD) and AD-related dementias (ADRD) mouse models and human AD/ADRD brain tissues. The project aims to generate single-cell spatial proteo-transcriptomics maps to molecularly characterize aberrant RNA splicing and abnormal protein products in specific...
- The National Institute on Aging (NIA) awarded a $442,357 Project Grant under the Aging Research program (CFDA 93.866) to the Research Foundation of the City University of New York (RFCUNY) on December 15, 2024. The grant aims to elucidate the molecular mechanisms that give rise to functionally neurodegenerative microglia, the brain's primary innate immune cells, which have been implicated as major determinants of Alzheimer's disease (AD) risk. The research will leverage novel mouse models and...
The National Institute on Aging (NIA), through the Aging Research Federal Grant Program (CFDA 93.866), awarded a $500,000 Project Grant to T-Neuro Inc. to confirm the use of aberrant T cells as an amyloid-independent blood biomarker for potentially earlier diagnosis and tracking the progression of Alzheimer's disease (AD). The award period is from August 1, 2025 to July 31, 2026. The project aims to demonstrate that alterations in age-related cytolytic (CD8) T cells can impact AD pathology upstream of amyloid-beta (Aβ) and hyperphosphorylated tau (pTau) abnormalities, potentially providing a simple blood-based biomarker for earlier AD detection and disease progression tracking. The research leverages the researchers' prior findings in a mouse model showing that certain age-related, self-peptide (amyloid precursor protein; APP)-specific CD8 T cells enter the brain, leading to AD-like pathologies. The goal is to confirm these observations in human AD and validate the T cell biomarker approach as a breakthrough in Alzheimer's diagnostics and drug development.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $500.0k | 7/29/25 |